近日，恒瑞医药宣布其全资子公司苏州盛迪亚生物医药有限公司收到国家药品监督管理局（NMPA）核准签发的《药物临床试验批准通知书》，同意其自主研发的SHR-2170注射液开展用于治疗晚期实体瘤的临床试验。SHR-2170是一种靶向OX40的单克隆抗体，属于免疫检查点激动剂，旨在通过激活T细胞增强机体对肿瘤的免疫应答。该药物的研发体现了恒瑞医药在肿瘤免疫治疗领域的持续布局与创新能力。OX40是T细胞共刺激受体，在抗肿瘤免疫反应中具有重要作用。通过激活OX40通路，SHR-2170有望打破肿瘤微环境中的免疫抑制状态，提升免疫系统对癌细胞的识别和清除能力。此次获批进入临床阶段，标志着该候选药物从实验室研究迈向人体验证的关键一步。恒瑞医药作为中国领先的创新型制药企业，近年来不断加大在生物药和创新小分子药物领域的研发投入。此次SHR-2170的临床试验获批，不仅丰富了公司在肿瘤免疫治疗管线中的产品组合，也为晚期实体瘤患者提供了潜在的新治疗选择。未来，恒瑞将继续推进该药物的临床开发，并探索与其他疗法的联合应用，以期为更多患者带来临床获益。
Recently, Hengrui Medicine announced that its wholly-owned subsidiary, Suzhou GrandE Bioscience Co., Ltd., has received a Drug Clinical Trial Approval Notice from China’s National Medical Products Administration (NMPA) for SHR-2170 injection, allowing it to proceed with clinical trials in patients with advanced solid tumors. SHR-2170 is a monoclonal antibody targeting OX40, functioning as an immune checkpoint agonist designed to enhance anti-tumor immune responses by activating T cells. This development underscores Hengrui’s ongoing commitment and innovation in the field of cancer immunotherapy.OX40 is a co-stimulatory receptor on T cells that plays a critical role in anti-tumor immunity. By activating the OX40 pathway, SHR-2170 aims to overcome immunosuppression within the tumor microenvironment and boost the immune system’s ability to recognize and eliminate cancer cells. The approval to enter clinical trials marks a pivotal transition from preclinical research to human testing for this investigational agent.As a leading innovative pharmaceutical company in China, Hengrui has significantly increased its R&D investment in biologics and novel small-molecule drugs in recent years. The clinical trial approval of SHR-2170 not only diversifies Hengrui’s oncology immunotherapy pipeline but also offers a potential new treatment option for patients with advanced solid tumors. Moving forward, Hengrui plans to advance the clinical development of SHR-2170 and explore its combination with other therapeutic modalities to maximize clinical benefits for patients.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/8752.html